Mesothelioma - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Immune Depletion to Enhance Immunotoxin Therapy
(Posted: 09/18/2013) - In this clinical trial, patients with advanced mesothelioma who have not benefited from previous chemotherapy will receive pentostatin and cyclophosphamide to prevent an anti-immunotoxin immune response prior to and in conjunction with SS1P immunotoxin therapy.
- Genetically Engineered Immunotherapy for Advanced Cancer
(Posted: 08/07/2012) - In this trial, doctors will collect T lymphocytes from the blood of patients with advanced mesothelin-expressing cancer and genetically engineer these cells to recognize mesothelin. The gene-engineered cells will then be multiplied and infused into the patients to fight their cancer.
- Combining Immunotoxin and Chemotherapy for Pleural Mesothelioma
(Posted: 07/14/2009) - In this trial, patients with inoperable epithelial pleural mesothelioma will be given SS1P immunotoxin in combination with pemetrexed and cisplatin to determine the maximum tolerated dose of SS1P and side effects profile in these patients.
- Combining Targeted Therapies for Thoracic Cancers
(Posted: 09/26/2006) - In this trial, patients with advanced thoracic cancers (cancers of the chest) or other cancers that have spread to the chest will be treated with the drugs romidepsin and flavopiridol. Researchers will study the safety of this combination and how these agents affect gene and protein expression in these patients.
- Chemotherapy and Biological Therapy for Advanced Mesothelioma
(Posted: 07/05/2005) - In this study, researchers are adding a biological agent called bevacizumab (Avastin®) to chemotherapy to see if it can help delay the progression of mesothelioma in patients with advanced mesothelioma.